期刊文献+

核酸适配体技术及其在肿瘤诊断和治疗中的应用 被引量:1

Aptamer Technology and Its Applications in Tumor Diagnosis and Therapy
原文传递
导出
摘要 核酸适配体是一类通过指数富集的配体系统进化(SELEX)技术获得的具有独特三维构象的小分子RNA或单链DNA。核酸适配体能高亲和力和高特异性与靶点结合,同时具有自身分子质量小、免疫原性低、热/化学稳定性高、靶标分子范围广等特点,广泛应用于疾病诊断、治疗、生物传感器、生物标志物筛选、新药研发等领域。综述近年来核酸适配体在肿瘤诊断和治疗方面的应用,并对核酸适配体的临床研究现状、市场前景及面临挑战和发展趋势作简要分析。 Aptamers are a class of small-sized RNA or single-stranded DNA oligonucleotides with characteristic 3D structures that are developed by SELEX (systematic evolution of ligands by exponential enrichment) technology. Functionally similar to antibodies, aptamers can recognize and bind to their cognate targets with high affinity and specificity. Moreover, aptamers have many unparalleled properties that are suitable for clinical applications and industrialization, such as smaller molecular weight, low immunogenicity, thermal stability, ease of conjugation or modification with different functional moieties, simple and low-cost chemical synthesis, and a wide range of potential biological targets. Currently, aptarner technology has been extensively used in various biomedical fields, including diagnostics, therapeutics, biosensors, biomarker screening, and drug discovery. In this article, the advances of aptamer technology and its applications in tumor diagnosis and therapy in the past few years were reviewed. Additionally, the clinical status, market prospect, current challenges and future directions of this rapidly advancing technology were briefly introduced.
出处 《药学进展》 CAS 2016年第8期583-595,共13页 Progress in Pharmaceutical Sciences
关键词 核酸适配体 基于指数富集的配体系统进化 肿瘤诊断 肿瘤治疗 aptamer SELEX tumor diagnosis tumor therapy
  • 相关文献

参考文献69

  • 1Serganov A, Patel D J. Ribozymes, riboswitches and beyond: regulation of gene expression without proteins[J]. Nat Rev Genet, 2007, 8(10): 776-790.
  • 2Sun H, Zu Y. A highlight of recent advances in aptamer technology and its application[J]. Molecules, 2015, 20(7): 11959-11980.
  • 3Sun H, Zhu X, LU P Y, et al. Oligonucleotide aptamers: new tools for targeted cancer therapy[J]. Mol Ther Nucleic Acids, 2014, 3: e 182.
  • 4Sun H, Zu Y. Aptamers and their applications in nanomedicine[J]. Small 2015, 11(20): 2352-2364.
  • 5Burmeister P E, Lewis S D, Silva R E et al. Direct in vitro selection of a 2'-O-methyl aptamer to VEGF[J]. Chem Biol, 2005, 12(1): 25-33.
  • 6Stovall G M, Bedenbaugh R S, Singh S, et al. h7 vitro selection using modified or unnatural nucleotides[J]. Cttrr Protoc Nucleic Acid Chem, 2014, 56: 1-33.
  • 7Keefe A D, Cload S T. SELEX with modified nucleotides[J]. Curr Opin Chem Biol, 2008, 12(4): 448-456.
  • 8Basile A S, Hutmacher M, Nickens D, et al. Population pharma- cokinetics of pegaptanib in patients with neovascular, age-related macular degeneration[J]. J CIh7 Pharmacol, 2012, 52(8): 1186- 1199.
  • 9Forster C, Zydek M, Rothkegel M, et al. Properties of an LNA-modified riein RNA aptamer[J]. Biochem Biophys Res Commun. 2012, 419(1): 60-65.
  • 10Bates P J, Laber D A, Miller D M, et al. Discovery and development of the G-rich oligonucleotide ASI411 as a novel treatment for cancer[J]. Exp Mol Pathol, 2009, 86(3): 151-164.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部